降脂疗法：联合使用效果更佳。 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

降脂疗法：联合使用效果更佳。 - Suppr | 超能文献

Lipid-lowering therapies: Better together.

作者信息

Banach Maciej, Penson Peter E

机构信息

Department of Hypertension, Medical University of Lodz (MUL), Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK; Liverpool Centre for Cardiovascular Science, Liverpool, UK.

出版信息

Atherosclerosis. 2021 Mar;320:86-88. doi: 10.1016/j.atherosclerosis.2021.01.009. Epub 2021 Jan 12.

DOI:10.1016/j.atherosclerosis.2021.01.009

Abstract

摘要

相似文献

1

Lipid-lowering therapies: Better together.降脂疗法：联合使用效果更佳。

Atherosclerosis. 2021 Mar;320:86-88. doi: 10.1016/j.atherosclerosis.2021.01.009. Epub 2021 Jan 12.

2

Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.贝匹地酸：对抗高血脂症的新工具。

Clin Ther. 2021 Feb;43(2):410-420. doi: 10.1016/j.clinthera.2020.12.001. Epub 2020 Dec 29.

3

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial.在高剂量阿托伐他汀背景治疗中添加贝匹地酸（ETC-1002）对高胆固醇血症患者的补充低密度脂蛋白胆固醇降低作用和药代动力学：一项随机安慰剂对照试验。

J Clin Lipidol. 2019 Jul-Aug;13(4):568-579. doi: 10.1016/j.jacl.2019.05.003. Epub 2019 May 13.

4

Bempedoic acid and ezetimibe - better together.贝派地酸与依折麦布——联用效果更佳。

Eur J Prev Cardiol. 2020 Apr;27(6):590-592. doi: 10.1177/2047487319864672. Epub 2019 Jul 16.

5

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.贝派地酸（ETC-1002）：一种ATP柠檬酸裂解酶的研究性抑制剂。

Curr Atheroscler Rep. 2016 Oct;18(10):61. doi: 10.1007/s11883-016-0611-4.

6

Comment on 'Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials'.关于“贝派地酸与依折麦布治疗高胆固醇血症：随机II/III期试验的系统评价与荟萃分析”的评论

Clin Drug Investig. 2021 May;41(5):493-494. doi: 10.1007/s40261-021-01029-2. Epub 2021 Apr 7.

7

Authors' Reply to 'Comment on: Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials'.作者对《关于：贝派地酸与依折麦布治疗高胆固醇血症：随机II/III期试验的系统评价和荟萃分析》的评论的回复

Clin Drug Investig. 2021 May;41(5):495-496. doi: 10.1007/s40261-021-01030-9. Epub 2021 Apr 11.

8

Bempedoic acid (Nexletol) for lowering LDL-cholesterol.贝派地酸（Nexletol）用于降低低密度脂蛋白胆固醇。

Med Lett Drugs Ther. 2020 Apr 6;62(1595):53-55.

9

[Opportunities and perspectives for bempedoic acid use in clinical practice].

G Ital Cardiol (Rome). 2021 Apr;22(4 Suppl 1):22S-27S. doi: 10.1714/3582.35673.

10

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.评估阿托伐他汀+依折麦布固定剂量复方制剂治疗高胆固醇血症的疗效和安全性。

Expert Opin Pharmacother. 2019 Jun;20(8):917-928. doi: 10.1080/14656566.2019.1594776. Epub 2019 Mar 25.

引用本文的文献

1

Evaluating the effects of bempedoic acid on lipid profiles and cardiovascular risk: An umbrella review of meta-analyses.评估贝派地酸对血脂谱和心血管风险的影响：一项荟萃分析的伞状综述

Qatar Med J. 2025 Jul 5;2025(2):51. doi: 10.5339/qmj.2025.51. eCollection 2025.

2

Considerations on the sustainability of hypercholesterolemia treatment in the context of new drugs on the market: data from Campania, Italy.基于市场上新药背景下对高胆固醇血症治疗可持续性的考量：来自意大利坎帕尼亚的数据

Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 8. doi: 10.1007/s00210-025-03862-0.

3

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP).

《2024年关于在已确诊的动脉粥样硬化性心血管疾病及急性冠状动脉综合征后优化使用降脂治疗的建议：国际脂质专家小组（ILEP）立场文件》

Drugs. 2024 Dec;84(12):1541-1577. doi: 10.1007/s40265-024-02105-5. Epub 2024 Nov 4.

4

Study of Lipid-Modifying Therapy Use and Risk Factor Management in Patients With Dyslipidemia in Duhok City/Kurdistan Region, Iraq.伊拉克库尔德地区杜胡克市血脂异常患者脂质调节治疗的使用及危险因素管理研究

Cureus. 2024 Feb 8;16(2):e53849. doi: 10.7759/cureus.53849. eCollection 2024 Feb.

5

Myeloid BAF60a deficiency alters metabolic homeostasis and exacerbates atherosclerosis.髓系 BAF60a 缺乏改变代谢稳态并加剧动脉粥样硬化。

Cell Rep. 2023 Oct 31;42(10):113171. doi: 10.1016/j.celrep.2023.113171. Epub 2023 Sep 27.

6

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.强化他汀治疗与他汀联合依折麦布 upfront 治疗急性冠脉综合征患者：基于 PL-ACS 数据的倾向性评分匹配分析。

J Am Heart Assoc. 2023 Sep 19;12(18):e030414. doi: 10.1161/JAHA.123.030414. Epub 2023 Sep 6.

7

Cholesterol-Lowering Drugs as Potential Antivirals: A Repurposing Approach against Flavivirus Infections.降脂药物作为潜在的抗病毒药物：针对黄病毒感染的再利用方法。

Viruses. 2023 Jun 28;15(7):1465. doi: 10.3390/v15071465.

8

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.2022年：心血管疾病之年——起始联合降脂治疗之年

Arch Med Sci. 2022 Nov 7;18(6):1429-1434. doi: 10.5114/aoms/156147. eCollection 2022.

9

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).逐步诊断和管理他汀类药物相关肌肉症状患者的安慰剂/反安慰剂效应：国际脂质专家组（ILEP）的立场文件。

J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960. Epub 2022 Mar 10.

10

Atherosclerosis: From Molecular Biology to Therapeutic Perspective.动脉粥样硬化：从分子生物学到治疗视角。

Int J Mol Sci. 2022 Mar 22;23(7):3444. doi: 10.3390/ijms23073444.